Optimization of the intravenous glucose tolerance test in T2DM patients using optimal experimental design

W Ben · Journal of Pharmacokinetics and Pharmacodynamics · 2009

Summary

It is concluded that improvement can be made to the design of the insulin modified IVGTT and that the most important design factor was the placement of sample times followed by the use of an optimal insulin dose.

Type: article
Published: 2009-06-25
Cited by: 21
References: 23
DOI: https://doi.org/10.1007/s10928-009-9123-y
PubMed: https://pubmed.ncbi.nlm.nih.gov/19554431/
OpenAlex: https://openalex.org/W19554431
Semantic Scholar: https://api.semanticscholar.org/CorpusID:11446164

Keywords

Political science, Business

References

An Integrated Model for Glucose and Insulin Regulation in Healthy Volunteers and Type 2 Diabetic Patients Following Intravenous Glucose ProvocationsHanna E. Silber, Petra M. Jauslin, Nicolas Frey — 2007
Simultaneous optimal experimental design on dose and sample timesCaridad Sánchez Acedo, Joaquín Quílez, Fernando López Bernad — 2009
Robust Optimal Design for the Estimation of Hyperparameters in Population PharmacokineticsMichel Tod, France Mentré, Yann Merlé — 1998
Modified protocols improve insulin sensitivity estimation using the minimal model.Yan Yang, Jang H. Youn, Richard N. Bergman — 1987
Robust Population Pharmacokinetic Experiment DesignMichael Dodds, Andrew C. Hooker, Paolo Vicini — 2005
POPED, a software for optimal experiment design in population kineticsMarco Foracchia, Andrew C. Hooker, Paolo Vicini — 2004
Pharmacokinetic/Pharmacodynamic Modelling in Diabetes MellitusCornelia B. Landersdorfer, William J. Jusko — 2008
Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative.Henrik Agersø, Paolo Vicini — 2003
A reduced sampling schedule for estimating the parameters of the glucose minimal model from a labeled IVGTTClaudio Cobelli, Alfredo Ruggeri — 1991
Robust experiment design via stochastic approximationLuc Pronzato, Éric Walter — 1985
Minimal model analysis of intravenous glucose tolerance test-derived insulin sensitivity in diabetic subjects.Susan Welch, Suzanne S P Gebhart, Richard N. Bergman — 1990
Intravenous Glucose Tolerance as a Tool in Definition and Diagnosis of Diabetes Mellitus*K Lundbæk — 1962
Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designsSylvie Retout, Stephen B. Duffull, France Mentré — 2001
Quantitative estimation of insulin sensitivity.Richard N. Bergman, Y.Z. Ider, C R Bowden — 1979
Approaches to handling pharmacodynamic baseline responsesC. Dansirikul, Hanna E. Silber, Mats O. Karlsson — 2008
The Insulin Sensitivity Index in Nondiabetic Man: Correlation Between Clamp-derived and IVGTT-derived ValuesJames C Beard, Richard N. Bergman, W. Kenneth Ward — 1986
Further Developments of the Fisher Information Matrix in Nonlinear Mixed Effects Models with Evaluation in Population PharmacokineticsSylvie Retout, France Mentré — 2003
The iterative two-stage population approach to IVGTT minimal modeling: improved precision with reduced sampling. Intravenous glucose tolerance test.Paolo Vicini, Claudio Cobelli — 2001
Bayesian Optimal Designs for Pharmacokinetic Models: Sensitivity to UncertaintyAristides Dokoumetzidis, Leon Aarons — 2007
[Intravenous glucose tolerance test].J. D. Kruse-Jarres, C. Hilpert, Kyle Grohmann — 1971

Cited by

Characterization of frequently sampled intravenous glucose tolerance test using scaling and sensitivity analysis of MINMODKiran Kiran, Manoj Kandpal, S. Lakshminarayanan — 2010
Modelling endocrine regulation of glycaemic control in animal models of diabetesEdmund M. Watson — 2014
Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice.Vidya Perera, Robert R. Bies, Gary Mo — 2014
Semimechanistic model describing gastric emptying and glucose absorption in healthy subjects and patients with type 2 diabetesOskar Alskär, Jonatan I. Bagger, Rikke Meldgaard Røge — 2016
Clinical Trial Simulation: A ReviewNicholas H. G. Holford, Subhrojyoti R.C., Bart A. Ploeger — 2010
Population based optimal experimental design in cancer diagnosis and chemotherapy: In silico analysisKanchi Lakshmi Kiran, S. Lakshminarayanan — 2013
Model‐based design of experiments for cellular processesAnkush Chakrabarty, Gregery T. Buzzard, Ann E. Rundell — 2013
An integrated model for the glucose-insulin system.Hanna E. Silber, Petra M. Jauslin, Nicolas Frey — 2010
D optimal designs for three Poisson dose–response modelsAlan Maloney, Ulrika S. H. Simonsson, Marloes Schaddelee — 2013
Model‐Based Interspecies Scaling of Glucose HomeostasisOskar Alskär, Mats O. Karlsson, Maria C. Kjellsson — 2017
Reduced and optimized trial designs for drugs described by a target mediated drug disposition modelAri Brekkan, Siv Jönsson, Mats O. Karlsson — 2018
Translation Between Two Models; Application with Integrated Glucose Homeostasis ModelsMoustafa M. A. Ibrahim, Anna Largajolli, Maria C. Kjellsson — 2019
Model-Based Conditional Weighted Residuals Analysis for Structural Model AssessmentMoustafa M. A. Ibrahim, Sebastian Ueckert, Svetlana Freiberga — 2019
Pharmacometric models in the development of biological medicinal productsAri Brekkan — 2019
On Optimal Designs for Clinical Trials: An Updated ReviewOleksandr Sverdlov, Yevgen Ryeznik, Weng Kee Wong — 2019
Development of early diagnosis of Parkinson's disease: Illusion or reality?M. V. Ugrumov — 2020
Optimal Designs for Model‐Based Assessment of Insulin Sensitivity and Glucose EffectivenessMoustafa M. A. Ibrahim, Erik Redestad, Maria C. Kjellsson — 2020
Accelerated Predictive Healthcare Analytics with Pumas, A High Performance Pharmaceutical Modeling and Simulation PlatformChristopher Rackauckas, Yingbo Ma, Andreas Noack — 2020
A snapshot of the vast array of diamagnetic CEST MRI contrast agentsDario Livio Longo, Antonella Carella, Alessia Corrado — 2022
Optimal Experimental Design to Estimate Insulin Response in Type 2 DiabetesSarah Ellinor Engell, Henrik Bengtsson, Karim Davari Benam — 2023

Related papers

No related papers recorded.